Latest Regulatory Approval News

Chariot Resources Ltd (ASX: CC9) has independently confirmed the presence of spodumene and pollucite in verification samples from its Fonlo and Iganna lithium projects in Nigeria, reinforcing the interpretation of these sites as lithium-caesium-tantalum pegmatite systems and informing upcoming metallurgical and exploration activities.

Bayan Mining and Minerals Limited has verified key rare earth element minerals at its Desert Star project in California, confirming a phosphate-rich hard-rock system dominated by light rare earth elements. The company is advancing towards its maiden drill program following regulatory approvals.

Condor Energy has agreed to acquire Jaguar Exploration’s 20% stake in the TEA 86 offshore Peru project, moving to full ownership. The deal, structured through performance shares, aims to simplify equity and support licence conversion and future partnerships.

Aguia Resources’ Brazilian subsidiary has achieved a key regulatory milestone with official fertiliser registration, enabling commercial sales of its PAMPAFOS phosphate product in Brazil’s large agricultural market.

Predictive Discovery Limited (ASX: PDI) and Robex Resources Inc. (ASX: RXR) have confirmed their merger is unconditional and moving to implementation, forming a significant West African gold producer with combined assets targeting over 400,000 ounces of gold production annually by 2029.

Zenith Minerals (ASX: ZNC) has commenced an eight-hole reverse circulation drilling program at its Consolidated Dulcie Gold Project, aiming to grow and enhance its recently defined 675,000 ounce inferred gold resource. The campaign targets near-resource zones and strategic gaps along a 6 km mineralised corridor, while regional exploration efforts continue.

National Storage REIT (ASX:NSR) has confirmed satisfaction of key foreign investment conditions for its proposed acquisition by a Brookfield-GIC consortium, with securityholder meetings scheduled for mid-April.

Archer Materials has progressed its Biochip program by completing the alpha prototype and Stage 1 project with IMEC, now advancing to develop a beta prototype suitable for external use and clinical validation.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) reported net sales of US$30.3 million for its FDA-approved cellular therapy Ryoncil in the March quarter, bringing total revenue since launch close to US$100 million. Strong sales in February and March offset January’s seasonal dip.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Elanor Investors Group has completed documentation for a $125 million balance sheet recapitalisation with Rockworth Capital Partners, preparing to release HY26 financial results and advance leadership renewal and rebranding initiatives.

Cue Energy Resources Limited’s Independent Board Committee has unanimously advised shareholders to reject Horizon Oil Limited’s off-market takeover offer, citing undervaluation and significant risks. Shareholders are urged to take no action in response to the offer.